ITC Begins Section 337 Investigation on Antirheumatic Drug
The International Trade Commission officially opened an investigation into alleged misappropriation of trade secrets relating to the manufacture of the antirheumatic drug Adalimumab. The investigation (ITC Inv. No. 337-TA-1296) is based on a complaint filed by AbbVie Dec. 17 (see…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
2112230048), alleging that Alvotech, Teva Pharmaceutical Industries and Ivers-Lee engaged in "a scheme to improperly recruit employees with knowledge of AbbVie's manufacturing process for Adalimumab," in an attempt to market a biosimilar called AVT02. AbbVie asked the ITC to issue a limited exclusion order and cease and desist orders banning importation and sale of covered goods by Alvotech, Teva and Ivers-Lee and their affiliates.